Neurocrine Biosciences (NBIX) Earnings Date, Estimates & Call Transcripts → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free NBIX Stock Alerts $135.99 -1.77 (-1.28%) (As of 04/26/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 1Before Market OpensConfirmedActual EPS (Feb. 7) $1.44 Beat By $0.31 Consensus EPS (Feb. 7) $1.13 Read Call TranscriptListen to CallLatest SEC 10-Q Filing Get Neurocrine Biosciences Earnings AlertsEnter your email address below to receive the latest news and earnings results for NBIX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueNBIX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NBIX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 Neurocrine Biosciences Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20244$0.67$1.09$0.94 Q2 20244$1.14$1.27$1.21 Q3 20244$1.18$1.49$1.39 Q4 20243$1.46$1.96$1.66 FY 202415$4.45$5.81$5.18 Q1 20251$1.28$1.28$1.28 Q2 20251$1.56$1.56$1.56 Q3 20251$1.75$1.75$1.75 Q4 20251$1.99$1.99$1.99 FY 20254$6.58$6.58 $6.58NBIX Earnings Date and InformationNeurocrine Biosciences last issued its earnings data on February 7th, 2024. The reported $1.44 earnings per share for the quarter, topping analysts' consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. Its revenue for the quarter was up 25.0% compared to the same quarter last year. Neurocrine Biosciences has generated $2.42 earnings per share over the last year ($2.42 diluted earnings per share) and currently has a price-to-earnings ratio of 56.2. Earnings for Neurocrine Biosciences are expected to grow by 31.20% in the coming year, from $4.84 to $6.35 per share. Neurocrine Biosciences has confirmed that its next quarterly earnings report will be published on Wednesday, May 1st, 2024. Neurocrine Biosciences will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call.. Read More Neurocrine Biosciences Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/1/2024Confirmed)------- 2/7/2024Q4 2023$1.13$1.44+$0.31$1.44$518.52 million$515.20 million 10/31/2023Q3 2023$0.91$0.82($0.09)$0.82$479.09 million$498.80 million 8/1/2023Q2 2023$0.77$0.95+$0.18$0.95$448.29 million$452.70 million5/3/2023Q1 2023$0.26($0.79)($1.05)($0.79)$412.96 million$420.40 million2/6/2023Q4 2022$1.15$1.24+$0.09$0.88$408.96 million$412.00 million 11/1/2022Q3 2022$0.84$0.69($0.15)$0.69$378.05 million$387.90 million Get the Latest News and Ratings for NBIX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. 8/4/2022Q2 2022$0.56($0.18)($0.74)($0.18)$340.62 million$378.20 million5/4/2022Q1 2022$0.33$0.14($0.19)$0.14$304.07 million$310.60 million 2/11/2022Q4 2021$0.61($0.08)($0.69)($0.08)$317.72 million$312.00 million 11/1/2021Q3 2021$0.51$0.23($0.28)$0.23$297.02 million$296.00 million 8/2/2021Q2 2021$0.52$0.43($0.09)$0.43$274.47 million$288.90 million 5/4/2021Q1 2021$0.47$0.33($0.14)$0.33$247.81 million$236.60 million Neurocrine Biosciences Earnings - Frequently Asked Questions When is Neurocrine Biosciences's earnings date? Neurocrine Biosciences has confirmed that its next quarterly earnings data will be published on Wednesday, May 1st, 2024. Learn more on NBIX's earnings history. Did Neurocrine Biosciences beat their earnings estimates last quarter? In the previous quarter, Neurocrine Biosciences (NASDAQ:NBIX) reported $1.44 earnings per share (EPS) to beat the analysts' consensus estimate of $1.13 by $0.31. Learn more on analysts' earnings estimate vs. NBIX's actual earnings. How can I listen to Neurocrine Biosciences's earnings conference call? The conference call for Neurocrine Biosciences's latest earnings report can be listened to online. Listen to Conference Call How can I read Neurocrine Biosciences's conference call transcript? The conference call transcript for Neurocrine Biosciences's latest earnings report can be read online. Read Transcript How can I view Neurocrine Biosciences's earnings report? Neurocrine Biosciences's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Neurocrine Biosciences generate each year? Neurocrine Biosciences (NASDAQ:NBIX) has a recorded annual revenue of $1.89 billion. How much profit does Neurocrine Biosciences generate each year? Neurocrine Biosciences (NASDAQ:NBIX) has a recorded net income of $249.70 million. NBIX has generated $2.42 earnings per share over the last four quarters. What is Neurocrine Biosciences's price-to-earnings ratio? Neurocrine Biosciences (NASDAQ:NBIX) has a trailing price-to-earnings ratio of 56.19 and a forward price-to-earnings ratio of 28.10. What is Neurocrine Biosciences's EPS forecast for next year? Neurocrine Biosciences's earnings are expected to grow from $4.84 per share to $6.35 per share in the next year, which is a 31.20% increase. More Earnings Resources from MarketBeat Related Companies: RGEN Earnings Date EXEL Earnings Date HALO Earnings Date DNLI Earnings Date ADPT Earnings Date BIIB Earnings Date TECH Earnings Date QGEN Earnings Date PCVX Earnings Date RVMD Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:NBIX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.